Although both CPT and PARP inhibitors are thought to kill cancer cells by generating seDSBs (90), we verified that POLE1exo−/− and CTF18−/− cells were tolerant to olaparib (Figure 7E) because of its suppression of the PARP1-Polε exonuclease axis. Here, PARP1 is linked to cancer.